β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis

Wenjun Guo, Yuliya Pylayeva, Angela Pepe, Toshiaki Yoshioka, William J. Muller, Giorgio Inghirami, Filippo G. Giancotti

Research output: Contribution to journalArticle

324 Citations (Scopus)

Abstract

Amplification of the ErbB2 locus, which encodes a receptor tyrosine kinase, is common in aggressive breast tumors and correlates with poor prognosis. The mechanisms underlying ErbB2-mediated breast carcinoma progression remain incompletely defined. To examine the role of the signaling and cell-adhesion receptor β4 integrin during ErbB2-mediated tumorigenesis, we introduced a targeted deletion of the β4 signaling domain into a mouse model of ErbB2-induced mammary carcinoma. Loss of β4 signaling suppresses mammary tumor onset and invasive growth. Ex vivo studies indicate that β4 forms a complex with ErbB2 and enhances activation of the transcription factors STAT3 and c-Jun. STAT3 contributes to disruption of epithelial adhesion and polarity, while c-Jun is required for hyperproliferation. Finally, deletion of the β4 signaling domain enhances the efficacy of ErbB2-targeted therapy. These results indicate that β4 integrin promotes tumor progression by amplifying ErbB2 signaling and identify β4 as a potential target for molecular therapy of breast cancer.

Original languageEnglish (US)
Pages (from-to)489-502
Number of pages14
JournalCell
Volume126
Issue number3
DOIs
StatePublished - Aug 4 2006

Fingerprint

Integrins
Carcinogenesis
Breast
Breast Neoplasms
Tumors
STAT3 Transcription Factor
Cell adhesion
Receptor Protein-Tyrosine Kinases
Cell Adhesion
Amplification
Adhesion
Chemical activation
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Guo, W., Pylayeva, Y., Pepe, A., Yoshioka, T., Muller, W. J., Inghirami, G., & Giancotti, F. G. (2006). β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell, 126(3), 489-502. https://doi.org/10.1016/j.cell.2006.05.047

β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. / Guo, Wenjun; Pylayeva, Yuliya; Pepe, Angela; Yoshioka, Toshiaki; Muller, William J.; Inghirami, Giorgio; Giancotti, Filippo G.

In: Cell, Vol. 126, No. 3, 04.08.2006, p. 489-502.

Research output: Contribution to journalArticle

Guo, W, Pylayeva, Y, Pepe, A, Yoshioka, T, Muller, WJ, Inghirami, G & Giancotti, FG 2006, 'β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis', Cell, vol. 126, no. 3, pp. 489-502. https://doi.org/10.1016/j.cell.2006.05.047
Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell. 2006 Aug 4;126(3):489-502. https://doi.org/10.1016/j.cell.2006.05.047
Guo, Wenjun ; Pylayeva, Yuliya ; Pepe, Angela ; Yoshioka, Toshiaki ; Muller, William J. ; Inghirami, Giorgio ; Giancotti, Filippo G. / β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. In: Cell. 2006 ; Vol. 126, No. 3. pp. 489-502.
@article{7d1ecad874c04b1db8f78179ab996066,
title = "β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis",
abstract = "Amplification of the ErbB2 locus, which encodes a receptor tyrosine kinase, is common in aggressive breast tumors and correlates with poor prognosis. The mechanisms underlying ErbB2-mediated breast carcinoma progression remain incompletely defined. To examine the role of the signaling and cell-adhesion receptor β4 integrin during ErbB2-mediated tumorigenesis, we introduced a targeted deletion of the β4 signaling domain into a mouse model of ErbB2-induced mammary carcinoma. Loss of β4 signaling suppresses mammary tumor onset and invasive growth. Ex vivo studies indicate that β4 forms a complex with ErbB2 and enhances activation of the transcription factors STAT3 and c-Jun. STAT3 contributes to disruption of epithelial adhesion and polarity, while c-Jun is required for hyperproliferation. Finally, deletion of the β4 signaling domain enhances the efficacy of ErbB2-targeted therapy. These results indicate that β4 integrin promotes tumor progression by amplifying ErbB2 signaling and identify β4 as a potential target for molecular therapy of breast cancer.",
author = "Wenjun Guo and Yuliya Pylayeva and Angela Pepe and Toshiaki Yoshioka and Muller, {William J.} and Giorgio Inghirami and Giancotti, {Filippo G.}",
year = "2006",
month = "8",
day = "4",
doi = "10.1016/j.cell.2006.05.047",
language = "English (US)",
volume = "126",
pages = "489--502",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis

AU - Guo, Wenjun

AU - Pylayeva, Yuliya

AU - Pepe, Angela

AU - Yoshioka, Toshiaki

AU - Muller, William J.

AU - Inghirami, Giorgio

AU - Giancotti, Filippo G.

PY - 2006/8/4

Y1 - 2006/8/4

N2 - Amplification of the ErbB2 locus, which encodes a receptor tyrosine kinase, is common in aggressive breast tumors and correlates with poor prognosis. The mechanisms underlying ErbB2-mediated breast carcinoma progression remain incompletely defined. To examine the role of the signaling and cell-adhesion receptor β4 integrin during ErbB2-mediated tumorigenesis, we introduced a targeted deletion of the β4 signaling domain into a mouse model of ErbB2-induced mammary carcinoma. Loss of β4 signaling suppresses mammary tumor onset and invasive growth. Ex vivo studies indicate that β4 forms a complex with ErbB2 and enhances activation of the transcription factors STAT3 and c-Jun. STAT3 contributes to disruption of epithelial adhesion and polarity, while c-Jun is required for hyperproliferation. Finally, deletion of the β4 signaling domain enhances the efficacy of ErbB2-targeted therapy. These results indicate that β4 integrin promotes tumor progression by amplifying ErbB2 signaling and identify β4 as a potential target for molecular therapy of breast cancer.

AB - Amplification of the ErbB2 locus, which encodes a receptor tyrosine kinase, is common in aggressive breast tumors and correlates with poor prognosis. The mechanisms underlying ErbB2-mediated breast carcinoma progression remain incompletely defined. To examine the role of the signaling and cell-adhesion receptor β4 integrin during ErbB2-mediated tumorigenesis, we introduced a targeted deletion of the β4 signaling domain into a mouse model of ErbB2-induced mammary carcinoma. Loss of β4 signaling suppresses mammary tumor onset and invasive growth. Ex vivo studies indicate that β4 forms a complex with ErbB2 and enhances activation of the transcription factors STAT3 and c-Jun. STAT3 contributes to disruption of epithelial adhesion and polarity, while c-Jun is required for hyperproliferation. Finally, deletion of the β4 signaling domain enhances the efficacy of ErbB2-targeted therapy. These results indicate that β4 integrin promotes tumor progression by amplifying ErbB2 signaling and identify β4 as a potential target for molecular therapy of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=33746764457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746764457&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2006.05.047

DO - 10.1016/j.cell.2006.05.047

M3 - Article

C2 - 16901783

AN - SCOPUS:33746764457

VL - 126

SP - 489

EP - 502

JO - Cell

JF - Cell

SN - 0092-8674

IS - 3

ER -